ArticleKidney international2024

A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.

Edouard L Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.